Cargando…
Impact of the host environment on the antitubercular action of pyrazinamide
Pyrazinamide remains the only drug in the tuberculosis pharmacopeia to drastically shorten first-line therapy from nine to six months. Due to its unparalleled ability to sterilize non-replicating bacilli and reduce relapse rates, PZA is expected to be irreplaceable in future therapies against tuberc...
Autores principales: | Lamont, Elise A., Baughn, Anthony D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945238/ https://www.ncbi.nlm.nih.gov/pubmed/31669220 http://dx.doi.org/10.1016/j.ebiom.2019.10.014 |
Ejemplares similares
-
Second-line antitubercular therapy with ethionamide and pyrazinamide causing pellagroid dermatitis presenting as diffuse palmoplantar keratoderma
por: Kura, Mahendra M., et al.
Publicado: (2021) -
Anti-tubercular Activity of Pyrazinamide is Independent of trans-Translation and RpsA
por: Dillon, Nicholas A., et al.
Publicado: (2017) -
Deciphering the mechanism of action of antitubercular compounds with metabolomics
por: Sakallioglu, Isin T., et al.
Publicado: (2021) -
Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis
por: Ahmad, Zahoor, et al.
Publicado: (2012) -
Host Targeted Activity of Pyrazinamide in Mycobacterium tuberculosis Infection
por: Manca, Claudia, et al.
Publicado: (2013)